These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30026510)

  • 1. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.
    Sanlorenzo M; Vujic I; Esteve-Puig R; Lai K; Vujic M; Lin K; Posch C; Dimon M; Moy A; Zekhtser M; Johnston K; Gho D; Ho W; Gajjala A; Oses Prieto J; Burlingame A; Daud A; Rappersberger K; Ortiz-Urda S
    Sci Rep; 2018 Jul; 8(1):10902. PubMed ID: 30026510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
    Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
    Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
    Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
    Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
    Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
    Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
    Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
    Ryan MB; Finn AJ; Pedone KH; Thomas NE; Der CJ; Cox AD
    Mol Cancer Res; 2016 Oct; 14(10):1009-1018. PubMed ID: 27418645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
    Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
    Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
    Nguyen MQ; Teh JLF; Purwin TJ; Chervoneva I; Davies MA; Nathanson KL; Cheng PF; Levesque MP; Dummer R; Aplin AE
    J Invest Dermatol; 2020 Nov; 140(11):2242-2252.e7. PubMed ID: 32389536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian S; Davar D
    Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IQGAP1 is an oncogenic target in canine melanoma.
    Lee BH; Neela PH; Kent MS; Zehnder AM
    PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.
    Parris JLD; Barnoud T; Leu JI; Leung JC; Ma W; Kirven NA; Poli ANR; Kossenkov AV; Liu Q; Salvino JM; George DL; Weeraratna AT; Chen Q; Murphy ME
    Cancer Res Commun; 2021 Oct; 1(1):17-29. PubMed ID: 35187538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
    Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
    Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response.
    Randic T; Magni S; Philippidou D; Margue C; Grzyb K; Preis JR; Wroblewska JP; Nazarov PV; Mittelbronn M; Frauenknecht KBM; Skupin A; Kreis S
    Cell Rep; 2023 Jul; 42(7):112696. PubMed ID: 37379213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid.
    Xia Y; Chen J; Gong C; Chen H; Sun J
    Med Sci Monit; 2016 Apr; 22():1360-7. PubMed ID: 27104669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.